Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 295,000 shares, an increase of 116.8% from the June 30th total of 136,100 shares. Currently, 10.9% of the company’s stock are short sold. Based on an average daily volume of 488,800 shares, the days-to-cover ratio is presently 0.6 days.
Seelos Therapeutics Stock Performance
SEEL traded down $0.03 during trading on Friday, hitting $0.44. 298,842 shares of the company’s stock were exchanged, compared to its average volume of 1,329,906. The business’s 50 day moving average is $0.85 and its two-hundred day moving average is $4.14. Seelos Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $398.40.
Seelos Therapeutics (NASDAQ:SEEL – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.60) EPS for the quarter. The firm had revenue of $0.58 million during the quarter.
Hedge Funds Weigh In On Seelos Therapeutics
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
Featured Stories
- Five stocks we like better than Seelos Therapeutics
- What is Put Option Volume?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How is Compound Interest Calculated?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Where to Find Earnings Call Transcripts
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.